|
|
|
|
Zysolin(TM) Pre-clinical Data Supports Once-a-day Dosing In Humans
AlphaRx (OTC BB:ALRX) is pleased to report a significant breakthrough in the development of Zysolin(TM), an inhaled Tobramycin nanoparticle formulation utilizing the company's proprietary drug delivery platform, and intended for the...
|
|
|
Zysolin(TM) Pre-clinical Data Supports Once-a-day Dosing in Humans
AlphaRx's inhaled Tobramycin nanoparticle formulation provides 300% more availability than standard free drug in lung tissue, as demonstrated in a recent animal pharmacokinetic study.MARKHAM, ON, June 18 /PRNewswire-FirstCall/ -...
|
|
|
Zysolin Pre-clinical Data Supports Once-a-day Dosing in Humans
MARKHAM, ON, June 18 /PRNewswire-FirstCall/ -- AlphaRx (OTC BB:ALRX) is pleased to report a significant breakthrough in the development of Zysolin(TM), an inhaled Tobramycin nanoparticle formulation utilizing the company's proprietary...
|
|
|
Update Module 1481: Management of cystic fibrosis
What are the main treatments for CF?Physiotherapy helps clear thick mucus from the lungs to prevent infections and lung damage? Medication aims to prevent chest infections and replace the missing pancreatic enzymes. Which drugs are...
|
|
|
Scientists at University of Parma report research in life sciences
- (NewsRx.com) -- According to recent research from Parma, Italy, 'Tobramycin microparticulate powders containing the hydrophobic adjunct sodium stearate were studied for their use as pulmonary formulations in dry powder inhalers (see...
|
|
|
Wyeth's BLA for Prevnar 13 wins FDA priority review
Regulatory submissions expected in 2010 Top Stories Final results expected before the end of 2009 ApoB SNALP, designed to reduce the production of apolipoprotein B To support preclinical studies in development of AVI-4658 for treatment of...
|
|
|
PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward
MUNICH and MONTEREY, Calif., May 7 /PRNewswire/ -- PARI Pharma GmbH received an Orphan Drug Designation (ODD) by the European Commission based on a positive recommendation by the EMEA for inhaled PARI Tobramycin 100 delivered via a...
|
|
|
PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward
MUNICH and MONTEREY, Calif., May 7 /PRNewswire/ -- PARI Pharma GmbH received an Orphan Drug Designation (ODD) by the European Commission based on a positive recommendation by the EMEA for inhaled PARI Tobramycin 100 delivered via a...
|
|
|
Axentis Pharma wins orphan designation for lung infection drug
Fluidosomes-tobramycin, a liposomal formulation of tobramycin Top Stories SwabCap, an effective cleaning alternative In response to the submission of an abbreviated new drug application Attrius product line to provide physicians...
|
|
|
Warner Chilcott files new patent infringement lawsuit against Mylan
In response to the submission of an abbreviated new drug application Top Stories SwabCap, an effective cleaning alternative In response to the submission of an abbreviated new drug application Attrius product line to provide physicians a...
|
|
|
Cystic Fibrosis - Orphan Drug Designation for Innovative Treatment Against Lung Infections by Axentis Pharma A
ZURICH, Switzerland, April 30 /PRNewswire/ -- An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received orphan drug designation in the US.Axentis Pharma of Zurich, Switzerland announced today...
|
